Tela Bio Inc (TELA)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $37.06M
Last updated: Nov 17, 2026 at 11:06 AM ET
Tela Bio Inc (TELA) Stock Forecast
Analysts expect Tela Bio (TELA) to earn -$0.66 per share in the fiscal year ending Dec 31, 2026, on revenue of $76.78M. Of 5 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.20, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 80.0% |
| Hold | 1 | 20.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 8.3%.
- Fiscal year ending Dec 31, 2026
- -$0.66
- EPS consensus, revenue $76.78M
- Fiscal year ending Dec 31, 2027
- -$0.46
- EPS consensus, revenue $83.19M
- Next report
- Mar 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.66 | -$0.70 to -$0.62 | 3 | $76.78M | $76.40M to $77.60M | 4 |
| Dec 31, 2027 | -$0.46 | -$0.48 to -$0.44 | 3 | $83.19M | $80.10M to $87.72M | 5 |
Quarterly Estimates
The EPS consensus rises from -$0.12 for the quarter ending Dec 31, 2026 to -$0.11 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.12 | -$0.12 to -$0.12 | 5 | $20.29M | $18.82M to $22.25M | 5 |
| Mar 31, 2027 | -$0.11 | -$0.12 to -$0.10 | 2 | $20.01M | $19.40M to $21.34M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 4 |
| Fiscal year ending Dec 31, 2027 | 5 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.70.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.66 | -$0.70 | -$0.69 | -$0.69 | -$0.70 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.46 | -$0.45 | -$0.45 | -$0.46 | -$0.54 | N/A |
| Quarter ending Mar 31, 2027 | -$0.11 | -$0.11 | -$0.12 | -$0.12 | -$0.13 | N/A |
Frequently Asked Questions About TELA
What is the TELA stock forecast?
Consensus analyst estimates put Tela Bio's EPS at -$0.66 for the fiscal year ending Dec 31, 2026, on revenue of $76.78M. The consensus rating from 5 analysts is Buy.
How do analysts rate TELA stock?
Of 5 analysts covering Tela Bio, 0 rate it Strong Buy, 4 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TELA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.66, with estimates from -$0.70 to -$0.62 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.46, with estimates from -$0.48 to -$0.44 from 3 analysts.
What revenue do analysts expect from Tela Bio next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $76.78M, with estimates from $76.40M to $77.60M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $83.19M, with estimates from $80.10M to $87.72M.
How many analysts cover TELA?
5 analysts rate Tela Bio stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TELA pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts